{
  "citations" : [ {
    "@id" : "https://pharmgkb.org/literature/15090607",
    "@context" : "https://api.pharmgkb.org/jsonld/literature.jsonld",
    "id" : 15090607,
    "resourceId" : "26094938",
    "title" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.",
    "_sameAs" : "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675696",
    "authors" : [ "Saito Y", "Stamp L K", "Caudle K E", "Hershfield M S", "McDonagh E M", "Callaghan J T", "Tassaneeyakul W", "Mushiroda T", "Kamatani N", "Goldspiel B R", "Phillips E J", "Klein T E", "Lee M T M", "Clinical Pharmacogenetics Implementation Consortium" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ "Allopurinol", "Biomarkers, Pharmacological", "Drug Administration Schedule", "Genotype", "Guidelines as Topic", "HLA-B Antigens", "Humans" ],
    "month" : 1,
    "nonHuman" : false,
    "objCls" : "Literature",
    "page" : "36-7",
    "pgkbPublication" : true,
    "pubDate" : "2016-01-01T00:00:00-08:00",
    "summary" : "The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).",
    "type" : "Article",
    "version" : 5,
    "volume" : "99",
    "xrefs" : [ {"@id":"https://pharmgkb.org/crossReference/pmc/PMC4675696","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449286509,"resource":"PubMed Central","resourceId":"PMC4675696","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675696"}, {"@id":"https://pharmgkb.org/crossReference/pubMed/26094938","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449286508,"resource":"PubMed","resourceId":"26094938","_url":"https://www.ncbi.nlm.nih.gov/pubmed/26094938"}, {"@id":"https://pharmgkb.org/crossReference/doi/10.1002/cpt.161","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449286510,"resource":"DOI","resourceId":"10.1002/cpt.161","_url":"http://dx.doi.org/10.1002%2Fcpt.161"} ],
    "year" : 2016
  }, {
    "@id" : "https://pharmgkb.org/literature/15033427",
    "@context" : "https://api.pharmgkb.org/jsonld/literature.jsonld",
    "id" : 15033427,
    "resourceId" : "23232549",
    "title" : "Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.",
    "_sameAs" : "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416",
    "authors" : [ "Hershfield M S", "Callaghan J T", "Tassaneeyakul W", "Mushiroda T", "Thorn C F", "Klein T E", "Lee M T M" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ "PA166048814", "PA444318", "PA445738" ],
    "meshTerms" : [ "Alleles", "Allopurinol", "Dose-Response Relationship, Drug", "Genotype", "Gout", "Gout Suppressants", "HLA-B Antigens", "Humans", "Hyperuricemia", "Pharmacogenetics", "Stevens-Johnson Syndrome" ],
    "month" : 2,
    "nonHuman" : false,
    "objCls" : "Literature",
    "page" : "153-8",
    "pgkbPublication" : true,
    "pubDate" : "2013-02-01T00:00:00-08:00",
    "summary" : "Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B*58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.",
    "type" : "Article",
    "version" : 5,
    "volume" : "93",
    "xrefs" : [ {"@id":"https://pharmgkb.org/crossReference/pmc/PMC3564416","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449274192,"resource":"PubMed Central","resourceId":"PMC3564416","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416"}, {"@id":"https://pharmgkb.org/crossReference/pubMed/23232549","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449274191,"resource":"PubMed","resourceId":"23232549","_url":"https://www.ncbi.nlm.nih.gov/pubmed/23232549"}, {"@id":"https://pharmgkb.org/crossReference/doi/10.1038/clpt.2012.209","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449274193,"resource":"DOI","resourceId":"10.1038/clpt.2012.209","_url":"http://dx.doi.org/10.1038%2Fclpt.2012.209"} ],
    "year" : 2013
  } ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166105003",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166105003",
    "name" : "Annotation of CPIC Guideline for allopurinol and HLA-B",
    "cancerGenome" : false,
    "descriptiveVideoId" : "8LF_sTtUCXY",
    "guidelineGenes" : [ {
      "id" : 1449560778,
      "alleles" : [ {
        "id" : 1449560779,
        "_label" : "Other",
        "allele" : "Other",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558334",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1445558334,
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Absence",
          "termId" : "haplotypeTags:1445558334",
          "version" : 0
        },
        "version" : 0
      }, {
        "id" : 1449560780,
        "_label" : "*58:01",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1445558333,
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Presence",
          "termId" : "haplotypeTags:1445558333",
          "version" : 0
        },
        "haplotype" : {
          "@id" : "https://pharmgkb.org/haplotype/PA165987831",
          "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
          "objCls" : "Haplotype",
          "id" : "PA165987831",
          "symbol" : "HLA-B*58:01",
          "name" : "*58:01",
          "version" : 2
        },
        "version" : 0
      } ],
      "gene" : {
        "@id" : "https://pharmgkb.org/gene/PA35056",
        "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
        "objCls" : "Gene",
        "id" : "PA35056",
        "symbol" : "HLA-B",
        "name" : "major histocompatibility complex, class I, B",
        "version" : 40
      },
      "version" : 0
    } ],
    "history" : [ {
      "id" : 1183699762,
      "date" : "2012-10-17T00:00:00-07:00",
      "type" : "Create",
      "version" : 0
    }, {
      "id" : 1444841843,
      "date" : "2015-06-11T15:10:54.200-07:00",
      "description" : "Published update",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1444841850,
      "date" : "2015-06-12T08:50:16.155-07:00",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450042999,
      "date" : "2018-11-19T14:34:36.346-08:00",
      "description" : "Updated link to new guideline video",
      "type" : "Update",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/15090607","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15090607,"resourceId":"26094938","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675696","objCls":"Literature","type":"Article","xrefs":[{"@id":"https://pharmgkb.org/crossReference/pmc/PMC4675696","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449286509,"resource":"PubMed Central","resourceId":"PMC4675696","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675696"},{"@id":"https://pharmgkb.org/crossReference/pubMed/26094938","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449286508,"resource":"PubMed","resourceId":"26094938","_url":"https://www.ncbi.nlm.nih.gov/pubmed/26094938"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1002/cpt.161","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449286510,"resource":"DOI","resourceId":"10.1002/cpt.161","_url":"http://dx.doi.org/10.1002%2Fcpt.161"}]}, {"@id":"https://pharmgkb.org/literature/15033427","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15033427,"resourceId":"23232549","title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416","objCls":"Literature","type":"Article","xrefs":[{"@id":"https://pharmgkb.org/crossReference/pmc/PMC3564416","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449274192,"resource":"PubMed Central","resourceId":"PMC3564416","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416"},{"@id":"https://pharmgkb.org/crossReference/pubMed/23232549","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449274191,"resource":"PubMed","resourceId":"23232549","_url":"https://www.ncbi.nlm.nih.gov/pubmed/23232549"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1038/clpt.2012.209","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449274193,"resource":"DOI","resourceId":"10.1038/clpt.2012.209","_url":"http://dx.doi.org/10.1038%2Fclpt.2012.209"}]}, {"@id":"https://pharmgkb.org/literature/15100908","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15100908,"resourceId":"https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/","title":"CPIC® Guideline for Allopurinol and HLA-B – CPIC","_sameAs":"https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/","objCls":"Literature","type":"Web Page","xrefs":[{"@id":"https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1447983440,"resource":"URL","resourceId":"https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/","_url":"https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"}]} ],
    "recommendation" : true,
    "relatedAlleles" : [ ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA448320",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA448320",
      "name" : "allopurinol",
      "version" : 6
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA35056",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA35056",
      "symbol" : "HLA-B",
      "name" : "major histocompatibility complex, class I, B",
      "version" : 40
    } ],
    "source" : "Clinical Pharmacogenetics Implementation Consortium",
    "summaryMarkdown" : {
      "id" : 1447981950,
      "html" : "<p>Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (&quot;HLA-B*58:01-positive&quot;) due to significantly increased risk of allopurinol-induced SCAR.</p>\n",
      "version" : 0
    },
    "terms" : [ {"@id":"https://pharmgkb.org/ontologyTerm/cpicStatus/cpicStatus:1183847844","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":1183847844,"resource":"CPIC Status","term":"A","termId":"cpicStatus:1183847844"} ],
    "textMarkdown" : {
      "id" : 1447981949,
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/\" target=\"_blank\">CPIC&reg; guideline for allopurinol and HLA-B</a>.</p>\n<h3 id=\"january-2016-update\">January 2016 Update</h3>\n<p><em>Accepted article preview online June 2015</em></p>\n<p>The 2015 update of CPIC guidelines regarding allopurinol has been published in <em>Clinical Pharmacology and Therapeutics</em>.  Recent literature was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>.</p>\n<ul>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/content/guideline/publication/allopurinol/2015/26094938.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing: 2015 update </a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/content/guideline/publication/allopurinol/2015/26094938-supplement.pdf\" target=\"_blank\">2015 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<h3 id=\"february-2013\">February 2013</h3>\n<p><em>Advanced online publication December 2012</em></p>\n<ul>\n<li>Guidelines regarding the use of pharmacogenomic tests in dosing for allopurinol have been published in Clinical Pharmacology and Therapeutics by the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</li>\n<li>These guidelines are applicable to:\n<ul>\n<li>adults</li>\n</ul>\n</li>\n<li>Excerpt from the 2013 allopurinol dosing guidelines:\n<ul>\n<li>&quot;Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout; however, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR), which includes drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A variant allele of the human leukocyte antigen-B, HLA-B*5801, associates strongly with allopurinol-induced SCAR. We have summarized evidence from the published literatures and develop peer-reviewed guidelines for allopurinol use based on HLA-B genotype.&quot;</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/content/guideline/publication/allopurinol/2013/23232549.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing </a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/content/guideline/publication/allopurinol/2013/23232549-supplement.pdf\" target=\"_blank\">2013 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<h3 id=\"table-1-recommended-dosing-of-allopurinol-based-on-hla-b-genotype\">Table 1: Recommended dosing of allopurinol based on <em>HLA-B</em> genotype</h3>\n<table class=\"table\">\n<thead>\n<tr><th>Likely Phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Recommendations for allopurinol therapy</th><th>Classification of recommendation for allopurinol therapy</th></tr>\n</thead>\n<tbody>\n<tr><td>Low or reduced risk of allopurinol SCAR</td><td>Absence of <em>*58:01</em> alleles (reported as &quot;negative&quot; on a genotyping test)</td><td>*X/*X <sup>a</sup></td><td>Low or reduced risk of allopurinol SCAR</td><td>Use allopurinol per standard dosing guidelines</td><td>Strong</td></tr>\n<tr><td>Significantly increased risk of allopurinol SCAR</td><td>Presence of at least one <em>*58:01</em> allele (reported as &quot;positive&quot; on a genotyping test)</td><td><em>*58:01</em>/*X <sup>a</sup> <em>*58:01/*58:01</em></td><td>Significantly increased risk of allopurinol SCAR</td><td>Allopurinol is contraindicated</td><td>Strong</td></tr>\n</tbody>\n</table>\n<p><em>Adapted from Table 2 of the 2013 Guideline Manuscript</em></p>\n<p><sup>a</sup> *X = any <em>HLA-B</em> genotype other than <em>*58:01</em>.</p>\n<p><em>HLA-B</em> = human leukocyte antigen B</p>\n",
      "version" : 15
    },
    "userId" : "carrillo",
    "version" : 38,
    "xrefs" : [ {"@id":"https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1447983440,"resource":"URL","resourceId":"https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/","_url":"https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"} ]
  }
}